Does Cyclophosphamide Still Have a Role in the Treatment of Severe Inflammatory Eye Disease?

References

• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356–365
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984;11:1115–1126
   PubMed Web of Science ®Google Scholar
• Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology. 2004;111:960–965
   PubMed Web of Science ®Google Scholar
• Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377–384
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357:1027–1032
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76–85
   PubMed Web of Science ®Google Scholar
• Fauci AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med. 1978;64:890–894
   PubMed Web of Science ®Google Scholar
• Wakefield D, Di Girolamo N, Thurau S, et al. Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res. 2013;35:44–62
   PubMed Web of Science ®Google Scholar
• Buckley CE 3rd, Gills JP Jr. Cyclophosphamide therapy of Behcet's disease. J Allergy. 1969;43:273–283
   PubMedGoogle Scholar
• Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52:969–972
   PubMed Web of Science ®Google Scholar
• de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43:105--112
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Radwan A, Lebanan MO, Foster CS. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome. Ocul Immunol Inflamm. 2013;21:32–37
   Web of Science ®Google Scholar
• Santiago-Casas Y, Peredo RA, Vila LM. Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases. Lupus. 2013;22:324–327
   PubMed Web of Science ®Google Scholar
• Kallenberg CG. Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? Ann Rheum Dis. 2013;72:ii62–ii65
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461–2469
   PubMed Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Tsuji G, et al. Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study. Mod Rheumatol. 2013;23:89–96
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220
   PubMed Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20:18–26
   PubMed Web of Science ®Google Scholar
• Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:1--7
   PubMed Web of Science ®Google Scholar
• Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol. 2009;93:421–422, 548
   PubMed Web of Science ®Google Scholar
• Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009;60:1540–1547
   PubMed Web of Science ®Google Scholar
• Suelves AM, Arcinue CA, Gonzalez-Martin JM, et al. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology. 2013;120:1201–1209
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 1994;21:123–125
   PubMed Web of Science ®Google Scholar
• Buckley CE 3rd, Gills JP Jr. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med. 1969;124:29–35
   PubMed Web of Science ®Google Scholar
• Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina. 2005;25:1–18
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet's disease: randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–252
   PubMed Web of Science ®Google Scholar
• Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis. Can J Ophthalmol. 2009;44:e9–e12
   PubMedGoogle Scholar
• Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895–900
   PubMed Web of Science ®Google Scholar
• Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–869
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232
   PubMed Web of Science ®Google Scholar
• Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J. 1985;291:1457–1460
   PubMed Web of Science ®Google Scholar
• Harward LE, Mitchell K, Pieper C, et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2013;22:81–86
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med. 1997;29:199–206
   PubMed Web of Science ®Google Scholar